Nephrodite

What Nephrodite does

Nephrodite, Inc. is a private, pre-clinical medical device company developing Holly™, the first implantable continuous dialysis system designed to replace intermittent, clinic-based hemodialysis for patients with end-stage kidney disease (ESKD). Holly combines a surgically implanted hemofilter placed in the pelvis and connected to larger blood vessels with an external interface and a portable home unit used nightly, eliminating the need for arm grafts, fistulas, and thrice-weekly clinic visits that currently consume 600–800+ hours per patient per year. The system is built on a proprietary hemofiltration membrane platform augmented with edge computing, on-board intelligent sensors, and cloud connectivity that streams patient data for remote physician monitoring and individualized therapy adjustment; biocompatible materials are engineered for long-term implantation with no observed clotting, hemolysis, or leakage in the first successful 72-hour large animal study at the University of Michigan. The intended patient population comprises the 850,000+ US and ~3.5 million global ESKD patients — including bridge-to-transplant and destination-therapy cohorts — served via an enterprise field sales motion into transplant centers, dialysis clinics, and major health systems, with planned hardware sales of the device and a recurring consumables annuity from scheduled cartridge replacement. The company is headquartered in Atlanta, Georgia (with an operations presence in Mumbai, India), was founded in 2020 by Dr. Nikhil Shah and Dr. Hiep Nguyen, has 11–50 employees, and has secured FDA Breakthrough Device Designation (Dec 2025) plus FDA TAP selection (June 2026) — both firsts for an implantable kidney replacement system — while actively raising capital to fund GLP studies and first-in-human trials.

Name

Nephrodite

Legal name

Nephrodite, Inc.

Website

https://nephrodite.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Nephrodite is a private medical device company developing Holly™, an implantable continuous dialysis system for end-stage kidney disease patients. Founded in 2020 and based in Atlanta, the company is pre-commercial, holding FDA Breakthrough Device Designation and TAP selection as it prepares for first-in-human trials.

Ownership category

akta.pro rank

Product category

Implantable Dialysis Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Hemodialysis Machines & Systems (HLAHAKAA)

akta.pro secondary industries

Home Dialysis Equipment & Remote Monitoring (HLAHAKAG), Renal Replacement Therapy Consumables (Bloodlines, Filters, Cartridges) (HLAHAKAH)

Keywords

• Implantable dialysis device
• Continuous renal replacement therapy
• Hemofiltration membrane platform
• End-stage kidney disease treatment
• Portable home dialysis system

Headquarters

HQ city

Atlanta

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Holly Implantable Dialysis Device: Medical device sales model for the Holly implantable continuous dialysis system. The device consists of an internal implant and external interface with portable home unit, along with cartridge-based membrane system for scheduled replacement. Revenue will come from device sales, consumables (replacement cartridges), and associated professional services for implantation and follow-up care.
2. Cartridge/Membrane Consumables: Recurring revenue from cartridge-based membrane replacement system. The external interface connects to a small portable home unit used nightly, with scheduled cartridge replacement creating a recurring consumables revenue stream.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Nephrodite is developing Holly™, an investigational implantable continuous dialysis system for end-stage kidney disease. The product consists of a surgically implanted filter placed in the pelvis area connected to larger blood vessels, paired with an external interface and portable home unit used nightly, along with a cartridge-based membrane system for scheduled replacement. The device is designed to continuously filter waste, balance fluids, and manage electrolytes inside the body without requiring frequent clinic visits, freeing ESKD patients from thrice-weekly dialysis center treatment.

Product overview

Nephrodite offers the Holly™ platform, a first-of-its-kind implantable continuous dialysis system. The product consists of a surgically implanted filter paired with an external interface and portable home unit. The implantable component is placed in the pelvis area and connected to blood vessels, while the external interface enables nightly dialysis support and remote physician monitoring. The platform is designed as a true kidney replacement therapy alternative for patients with end-stage kidney disease.

Differentiator

Problem solved

Functional benefit

Brands

• Holly™: An implantable, continuous dialysis system designed to provide sustained toxin clearance and fluid balance without the burden of intermittent, clinic-based dialysis. Also referred to as Holly™ by Nephrodite.

Products and services

• Holly™ Implantable Continuous Dialysis System An implantable, continuous dialysis system for end-stage kidney disease patients that combines a surgically implanted hemofilter placed in the pelvis and connected to larger blood vessels with an external interface and portable home unit used nightly, plus a cartridge-based membrane system for scheduled replacement. The device continuously filters waste, balances fluids, and manages electrolytes inside the body, freeing patients from thrice-weekly in-center dialysis, needle sticks, and arm grafts while enabling at-home or on-the-go treatment with remote physician monitoring. It is designed as a true kidney replacement therapy alternative for use as continuous therapy, bridge-to-transplant, or destination therapy.

Quantifiable outcome

• First successful multi-day continuous kidney function replacement in a living organism (72-hour sheep study)
• +3 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• ATDC (Advanced Technology Development Center) at Georgia TechcoreStrategic or Co-development Partner · 20 March 2026ATDC is Georgia Tech's technology business incubator. Nephrodite joined ATDC's HealthTech portfolio and received coaching, programming, regulatory guidance, and access to Georgia Tech labs, facilities, prototyping support, and clinical advisors. The company was selected from thousands of applicants for CDL Rockies Prime stream. ATDC's HealthTech vertical is sponsored by Catalyst by Wellstar and includes medical devices, biotech, and digital health companies.
• Center for MedTech Excellence (Georgia Tech)minorStrategic or Co-development PartnerGeorgia Tech program providing additional support and resources for medical technology development alongside ATDC participation.
• Georgia Manufacturing Extension PartnershipminorStrategic or Co-development PartnerState program providing manufacturing expertise and support for product development and commercialization.
• Conrad Jobst Vascular Research Laboratories, University of MichigancoreStrategic or Co-development PartnerConducted the successful 72-hour multi-day large animal study demonstrating continuous kidney function replacement in a living sheep model. This critical preclinical milestone validated the Holly device's safety and performance.
• Creative Destruction Lab (CDL)coreStrategic or Co-development PartnerSeed-stage program for science-based companies providing objectives-based mentoring over nine months. Nephrodite was selected from thousands of applicants for the Rockies Prime stream and graduated in 2022, gaining access to experienced entrepreneurs, investors, and scientists for mentorship and guidance.
• Austin Technology IncubatorminorStrategic or Co-development PartnerTechnology business incubator at University of Texas where Nephrodite was added to its client portfolio as a life science company developing innovative implantable dialysis technology.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Fresenius Medical Care: World's largest dialysis services and products company, operating thousands of dialysis centers and manufacturing dialysis machines and consumables. A potential strategic acquirer and the dominant incumbent Nephrodite must displace or partner with in the U.S. ESKD market.
• Baxter International: Global medical device and pharmaceutical company with a significant peritoneal dialysis (PD) portfolio and renal care franchise. A potential strategic acquirer and incumbent in the broader renal replacement therapy market Holly targets.
• Medtronic: Large medical device incumbent with renal denervation and broader device franchises, providing a strategic acquirer profile and overlapping expertise in implantable, sensor-enabled therapeutic devices similar to Holly.
• DaVita: Largest U.S. dialysis services provider, operating the majority of outpatient dialysis clinics and increasingly invested in home dialysis modalities. Represents both a major customer channel and a competitive incumbent for any new dialysis technology adoption.

Direct peers

• Outset Medical: Maker of the Tablo Hemodialysis System, a console-based home and in-clinic dialysis device targeting the same ESKD patient population as Nephrodite's Holly. Most directly comparable as a venture-backed disruptor pursuing simpler, patient-friendly dialysis outside the clinic.

Emerging players

• Wearable Artificial Organs Inc. (WAK): Developer of the Wearable Artificial Kidney, a wearable dialysis device targeting continuous ambulatory dialysis. Closely comparable as an early-stage alternative modality pursuing freedom from chair-based dialysis for the same ESKD population.
• Quanta Dialysis Technologies: Developer of the SC+ portable hemodialysis system, a compact device for home and clinic use targeting the same patient population as Holly. A direct emerging competitor pursuing simpler, portable dialysis outside traditional centers.
• Diality: Developer of a portable hemodialysis system for use across in-clinic, acute, and home settings. Comparable as a venture-stage competitor pursuing flexible, patient-centric dialysis modalities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/nephrodite-inc
• Xx.com/NephroditeInc

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nephrodite